Bank of New York Mellon’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $48.3M | Sell |
197,226
-9,418
| -5% | -$2.04M | 0.01% | 1095 |
|
|
2026
Q1 | $34.9M | Sell |
206,644
-48,453
| -19% | -$8.37M | 0.01% | 1218 |
|
|
2025
Q4 | $46.6M | Buy |
255,097
+1,834
| +0.7% | +$256K | 0.01% | 1053 |
|
|
2025
Q3 | $30.8M | Buy |
253,263
+49,631
| +24% | +$5.59M | 0.01% | 1291 |
|
|
2025
Q2 | $21.3M | Buy |
203,632
+72,609
| +55% | +$7.69M | ﹤0.01% | 1482 |
|
|
2025
Q1 | $15.3M | Sell |
131,023
-3,527
| -3% | -$402K | ﹤0.01% | 1639 |
|
|
2024
Q4 | $11.4M | Sell |
134,550
-1,896
| -1% | -$174K | ﹤0.01% | 1862 |
|
|
2024
Q3 | $12.3M | Sell |
136,446
-29,118
| -18% | -$2.54M | ﹤0.01% | 1827 |
|
|
2024
Q2 | $13.3M | Buy |
165,564
+11,793
| +8% | +$873K | ﹤0.01% | 1810 |
|
|
2024
Q1 | $12.3M | Sell |
153,771
-12,522
| -8% | -$1.05M | ﹤0.01% | 1858 |
|
|
2023
Q4 | $13.2M | Sell |
166,293
-1,713
| -1% | -$115K | ﹤0.01% | 1824 |
|
|
2023
Q3 | $11.7M | Buy |
168,006
+6,920
| +4% | +$517K | ﹤0.01% | 1850 |
|
|
2023
Q2 | $11.6M | Buy |
161,086
+35,970
| +29% | +$2.65M | ﹤0.01% | 1864 |
|
|
2023
Q1 | $7.72M | Sell |
125,116
-3,382
| -3% | -$222K | ﹤0.01% | 2063 |
|
|
2022
Q4 | $9.91M | Sell |
128,498
-6,632
| -5% | -$396K | ﹤0.01% | 1950 |
|
|
2022
Q3 | $6.03M | Buy |
135,130
+17,720
| +15% | +$885K | ﹤0.01% | 2189 |
|
|
2022
Q2 | $4.5M | Buy |
117,410
+11,987
| +11% | +$379K | ﹤0.01% | 2373 |
|
|
2022
Q1 | $4.36M | Sell |
105,423
-16,556
| -14% | -$513K | ﹤0.01% | 2498 |
|
|
2021
Q4 | $4.61M | Sell |
121,979
-24,427
| -17% | -$899K | ﹤0.01% | 2505 |
|
|
2021
Q3 | $4.83M | Buy |
146,406
+8,107
| +6% | +$316K | ﹤0.01% | 2508 |
|
|
2021
Q2 | $9.33M | Sell |
138,299
-6,675
| -5% | -$401K | ﹤0.01% | 2177 |
|
|
2021
Q1 | $8.21M | Sell |
144,974
-5,445
| -4% | -$383K | ﹤0.01% | 2202 |
|
|
2020
Q4 | $12.3M | Buy |
150,419
+1,860
| +1% | +$139K | ﹤0.01% | 1900 |
|
|
2020
Q3 | $10.6M | Buy |
148,559
+1,520
| +1% | +$118K | ﹤0.01% | 1825 |
|
|
2020
Q2 | $12.1M | Sell |
147,039
-6,142
| -4% | -$473K | ﹤0.01% | 1722 |
|
|
2020
Q1 | $9.01M | Buy |
153,181
+6,556
| +4% | +$534K | ﹤0.01% | 1756 |
|
|
2019
Q4 | $15.2M | Sell |
146,625
-17,826
| -11% | -$720K | ﹤0.01% | 1733 |
|
|
2019
Q3 | $3.33M | Buy |
164,451
+55
| +0% | +$1.41K | ﹤0.01% | 2473 |
|
|
2019
Q2 | $4.23M | Buy |
164,396
+76,555
| +87% | +$1.53M | ﹤0.01% | 2416 |
|
|
2019
Q1 | $1.25M | Buy |
87,841
+53,151
| +153% | +$494K | ﹤0.01% | 3030 |
|
|
2018
Q4 | $98K | Buy |
+34,690
| New | +$114K | ﹤0.01% | 3960 |
|
|
2017
Q2 | – | Sell |
-22,723
| Closed | -$88K | – | 4299 |
|
|
2017
Q1 | $88K | Sell |
22,723
-8,195
| -27% | -$39.2K | ﹤0.01% | 4055 |
|
|
2016
Q4 | $208K | Buy |
30,918
+9,564
| +45% | +$67.2K | ﹤0.01% | 3894 |
|
|
2016
Q3 | $169K | Hold |
21,354
| – | – | ﹤0.01% | 3931 |
|
|
2016
Q2 | $161K | Buy |
+21,354
| New | +$197K | ﹤0.01% | 3956 |
|
|
2016
Q1 | – | Sell |
-11,512
| Closed | -$107K | – | 4216 |
|
|
2015
Q4 | $107K | Buy |
+11,512
| New | +$101K | ﹤0.01% | 4043 |
|
Other funds holding AXSM
N
EA
GIP
Bank of New York Mellon's AXSM Position: Q2 2026 in Review
Bank of New York Mellon reduced its Axsome Therapeutics (AXSM) stake by 4.6% in Q2 2026, selling an estimated $2.04M and leaving 197,226 shares worth $48.3M. The position accounts for 0.01% of the portfolio, ranked #1095.
Bank of New York Mellon first reported a position in AXSM in Q4 2015 and has held it in 36 quarters since. 209 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Bank of New York Mellon held 197,226 shares of Axsome Therapeutics worth $48.3M as of Q2 2026.
- Bank of New York Mellon sold 9,418 Axsome Therapeutics shares in Q2 2026, an estimated $2.04M.
- Axsome Therapeutics made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1095 holding.
- Bank of New York Mellon first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 36 quarters since.
- 209 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.